Premium
Myelodysplastic syndrome in a patient with adult T‐cell leukaemia
Author(s) -
Kawabata Hisashi,
Utsunomiya Atae,
Hanada Shuichi,
Makino Torahiko,
Takatsuka Yoshifusa,
Takeuchi Shogo,
Suzuki Shinsuke,
Suzumiya Junji,
Ohshima Kouichi,
Horiike Shigeo
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01610.x
Subject(s) - bone marrow , myelodysplastic syndromes , medicine , monoclonal , leukemia , chemotherapy , immunology , virology , monoclonal antibody , antibody
A 53‐year‐old female who developed myelodysplastic syndrome (MDS) after chemotherapy for adult T‐cell leukaemia (ATL) is described. The latent period of therapy‐related MDS (t‐MDS) from the time of diagnosis of ATL was approximately 35 months. Cytogenetic analysis of the bone marrow cells at the time of diagnosis of t‐MDS revealed a clonal abnormality; 46,XX,add(7)(p13), der(17)t(3;17)(p11;p13). Although monoclonal integration of human T lymphotropic virus type I (HTLV‐I) proviral DNA was detected in the peripheral blood lymphocytes at ATL diagnosis, bone marrow cells at t‐MDS diagnosis did not show monoclonal integration of HTLV‐I. To our knowledge, this is the first report of t‐MDS associated with ATL.